Circular <scp>RNA</scp> and pre‐eclampsia: on the long road from the laboratory to the bedside

Prefumo, Federico

doi:10.1111/1471-0528.13965

Cited by 8 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have identified some differentially expressed circRNAs in blood circulation [ 36 , 37 ] and PE placentas [ 38 ] using Agilent and KangChen circRNA microarrays, respectively. Because there are different gene probes between Agilent (approximately 90,000 probes) and KangChen (301 probes) circRNA microarrays (e.g., there are no expression probes for hsa-circRNA-100782, hsa-circRNA-102682, or hsa-circRNA-104820 in the Agilent circRNA microarray) [ 38 ], our findings did not conflict with their results.…”

Section: Discussionmentioning

confidence: 99%

Competing endogenous RNA expression profiling in pre-eclampsia identifies hsa_circ_0036877 as a potential novel blood biomarker for early pre-eclampsia

et al. 2018

Clin Epigenet

View full text Add to dashboard Cite

BackgroundThe etiology and pathogenesis of pre-eclampsia (PE) is unclear, and there is no ideal early clinical biomarker for prediction of PE. The competing endogenous RNA (ceRNA) hypothesis is a new approach to uncover the molecular pathology of PE. The first aim of this study was to perform messenger RNA, long non-coding RNA, and circular RNA (circRNA) expression profiling of human normal and severe pre-eclampsia (SPE) placentas. circRNA, which has a stable structure, is a more suitable biomarker than other types of RNA. Therefore, the second aim of our study was to select some differentially expressed circRNAs in PE placentas as early clinical biomarkers of PE in blood circulation.ResultsUsing microarray analysis, we investigated differentially expressed ceRNAs in human normal and SPE placentas. Bioinformatics, such as gene ontology, KEGG pathway, and ceRNA network analyses, were performed to evaluate the microarray data and gain further insights into the biological processes. RNAs (Chd5, Furin, lnc-ELAVL4-9:1, lnc-RAP1GAP2-5:2, hsa_circ_0036877, hsa_circ_0036878, hsa_circ_0055724, hsa_circ_0049730, and hsa_circ_0036474) were validated by quantitative real-time PCR (qRT-PCR). RNA immunoprecipitation (RIP) of AGO2 in htra-8 cells and qRT-PCR analysis of hsa_circ_0036877 expression in maternal whole peripheral blood samples of participants were then conducted to confirm that hsa_circ_0036877 is a ceRNA and potential novel blood biomarker for early PE, respectively.ConclusionOur study is the first systematic profiling of ceRNAs in placentas of PE patients and revealed the global ceRNA network integration in PE. Moreover, hsa_circ_0036877 can function as a ceRNA and serve as a potential novel blood biomarker for early PE.Electronic supplementary materialThe online version of this article (10.1186/s13148-018-0482-3) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Competing endogenous RNA expression profiling in pre-eclampsia identifies hsa_circ_0036877 as a potential novel blood biomarker for early pre-eclampsia

et al. 2018

Clin Epigenet

View full text Add to dashboard Cite

show abstract

“…Researchers have examined a significantly elevated SFLT-1/PlGF ratio in patients with PE caused by placental insufficiency [ 61 , 62 ]. Zhang et al combined circRNA with ENG to enhance the predictive power for early PE [ 63 ]. Another reason is that the above-mentioned molecules commonly used in clinical prediction are proteins, while our model is constructed based on the RNA level of the screened markers.…”

Section: Discussionmentioning

confidence: 99%

Establishment and validation of a predictive model of preeclampsia based on transcriptional signatures of 43 genes in decidua basalis and peripheral blood

Hong-ya

Zhang

et al. 2022

BMC Bioinformatics

View full text Add to dashboard Cite

Preeclampsia (PE) has an increasing incidence worldwide, and there is no gold standard for prediction. Recent progress has shown that abnormal decidualization and impaired vascular remodeling are essential to PE pathogenesis. Therefore, it is of great significance to analyze the decidua basalis and blood changes of PE to explore new methods. Here, we performed weighted gene co-expression network analysis based on 9553 differentially expressed genes of decidua basalis data (GSE60438 includes 25 cases of PE and 23 non-cases) from Gene Expression Omnibus to screen relevant module-eigengenes (MEs). Among them, MEblue and MEgrey are the most correlated with PE, which contains 371 core genes. Subsequently, we applied the logistic least absolute shrinkage and selection operator regression, screened 43 genes most relevant to prediction from the intersections of the 371 genes and training set (GSE48424 includes 18 cases of PE and 18 non-cases) genes, and built a predictive model. The specificity and sensitivity are illustrated by receiver operating characteristic curves, and the stability was verified by two validation sets (GSE86200 includes 12 cases of PE and 48 non-cases, and GSE85307 includes 47 cases of PE and 110 non-cases). The results demonstrated that our predictive model shows good predictions, with an area under the curve of 0.991 for the training set, 0.874 and 0.986 for the validation sets. Finally, we found the 43 key marker genes in the model are closely associated with the clinically accepted predictive molecules, including FLT1, PIGF, ENG and VEGF. Therefore, this predictive model provides a potential approach for PE diagnosis and treatment.

show abstract

“…Multiple studies found that single circRNAs yield good diagnostic performance in tissue or plasma (Shang et al, ; Sun, Tang, et al, ; Wang, Li, et al, ; Zong et al, ). Moreover, several studies provided that single circRNAs in combination with other plasma protein biomarkers such as CEA, CA‐15.3, CA‐125 and AFP possess better diagnostic performance (Huang et al, ; Prefumo, ; Yang et al, ; Yin et al, ; Zhang, Yang, et al, ). Additionally, a single circRNA combined with other circRNAs obtained also had better diagnostic accuracy (Li, Chen, et al, ; Li, Shao, et al, ; Ren & Xin, ).…”

Section: Discussionmentioning

confidence: 99%

Diagnostic performance of circular RNAs in human cancers: A systematic review and meta‐analysis

et al. 2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

Background Recently, accumulating evidence have revealed that circular RNA (circRNA) was deregulated in multiple types of cancer, suggesting that circRNA might serve as a novel candidate biomarker of cancer diagnosis. However, inconsistent results have become an obstacle in applying circRNAs to clinical practice. The aim of this study is to evaluate diagnostic value of circRNAs among cancers. Methods A literature search was systematically performed among PubMed, Sciencedirect, Cochrane Library, Web of Science, Wanfang, and Chinese National Knowledge Infrastructure databases up to February 15, 2019. The pooled sensitivity (SEN), specificity (SPE), positive likelihood ratios, negative likelihood ratios, diagnostic odds ratio, and area under the SROC curve (AUC) were applied to evaluate diagnostic performance of circRNAs. Results In total, the study included 64 studies with single circRNA and 13 studies with combined circRNAs. Overall, the study presented that a single circRNA had moderate diagnostic value, with a SEN of 0.75, a SPE of 0.76, and an AUC of 0.82. The plasma circRNAs had higher diagnostic accuracy than tissue (AUC: 0.87, 95% confidence interval [CI]: 0.83–0.89 for plasma/serum subgroup; AUC: 0.79, 95% CI: 0.75–0.82 for tissue subgroup). Furthermore, the combined circRNAs had good diagnostic efficacy for GC, with a SEN of 0.89, a SPE of 0.94, and an AUC of 0.97, respectively. Conclusion This study confirmed that circRNAs may be candidate biomarkers for cancer diagnosis. In particular, diagnosis of combined circRNAs will be a new alternative applied to clinical research and practice for cancer.

show abstract

Circular RNA and pre‐eclampsia: on the long road from the laboratory to the bedside

Cited by 8 publications

References 0 publications

Competing endogenous RNA expression profiling in pre-eclampsia identifies hsa_circ_0036877 as a potential novel blood biomarker for early pre-eclampsia

Competing endogenous RNA expression profiling in pre-eclampsia identifies hsa_circ_0036877 as a potential novel blood biomarker for early pre-eclampsia

Establishment and validation of a predictive model of preeclampsia based on transcriptional signatures of 43 genes in decidua basalis and peripheral blood

Diagnostic performance of circular RNAs in human cancers: A systematic review and meta‐analysis

Contact Info

Product

Resources

About